Prophylactic effect of tamoxifen against induction of mammary carcinoma
Author(s) -
Gabri Ms,
Osman Am,
El-Sayed Mm,
Negm Somaia.A
Publication year - 2004
Publication title -
the egyptian journal of hospital medicine
Language(s) - English
DOI - 10.12816/ejhm.2004.18225
Tamoxifen (TAM) is a potent anticancer agent known to interrupt the enhanced estrogen activity of malignant mammary gland cells, The mechanism of tamoxifen’s anti-tumor activity is primarily due to its anti estrogen action. Female Swiss albino mice were used in the present study and divided into:normal control group, two Ehrlich ascites carcinoma (EAC) control groups [treated interaperitonealy(IP) and subcutaneously (Sc)], tamoxifen treated only group, tamoxifen pre treated then EAC (S.C) injected group and tamoxifen pre treated then EAC (I.P) injected group. The present results showed a significant decrease in tumor volume and a significant increase in the survival time in the pre-treated group compared to untreated group. There was a pathological change in the uterine tissues of the tamoxifen treated mice in the form of squamous metaplasia and dysplasia of glandular epithelial . The kidney tissues showed a minimal pathological change in the form of a focal renal lesion in the renal tubular epithelium. in conclusion the present study showed that tamoxifen has a prophylactic effect against experimental mammary carcinoma. And exerts some side effects on the histopathological structure of the uterine and kidney tissues.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom